The specific elements in a T cell-dependent immune response to a protein are: the peptide antigen; the MHC molecule, which binds the peptide antigen; and the cognate receptor of the T cell, which recognizes the peptide-MHC complex. Accessory costimulator molecules are required for a normal immune response but do not account for its specificity and diversity. Therapy to modify immune responses in a specific manner should therefore logically be targeted to one or more of these specific elements. A range of strategies (Table 1 ) centered on antigen, MHC molecule, or T cell receptor (TCR) have been shown to prevent the induction or favorably modify the natural history of autoimmune disease in rodents. Strategies centered on autoantigens have a clear advantage in human autoimmune disease. Theoretically, autoantigen-based therapy is generic (i.e., applicable to all individuals [who exhibit immunity, presumed pathogenic, to the autoantigen]), whereas the utility of MHC molecules or TCRs at the population level is limited by their polymorphism.
TWO SIDES TO AN AUTOANTIGEN: PATHOGEN AND PANACEA
In considering antigen-specific therapy, an apparent dilemma for human autoimmunologists is the finding of immunity to multiple autoantigens even in so-called organ-specific autoimmune diseases: for example, insulin-dependent diabetes mellitus (IDDM) (1) (3) . Antigens in these animal models, including insulin (4) and GAD (5) (6) (7) in the NOD mouse, have been used as therapeutic agents to induce immune tolerance and modify favorably the natural history of disease. This demonstrates that they elicit immunity that is not only a disease marker, but is also pathogenic.
Demonstrating that an autoantigen is a therapeutic tolerogen in an animal model is an important criterion of pathogenicity that can now be applied to autoimmune disease in humans. 
ANTIGEN-SPECIFIC TOLERANCE
Antigen-specific modification of immune responses was described before the modern era of immunology (8) and probably underlies primitive "desensitization" procedures like deliberate exposure to poison ivy by native Indians. Antigen-specific tolerance may operate directly on effector T cells or via regulatory T cells by several mechanisms that are not necessarily mutually exclusive (Table 2) , depending on the mode of antigen administration and other factors such as antigen dose. In the mouse, parenteral, highdose soluble protein antigen has been shown to and/or transforming growth factor-,3 (13 Based on results in the rodent models (15,16), a small pilot study (25) suggested that parenteral insulin might delay the onset of IDDM in humans. This form of intervention will now be tested in a large, randomized trial, the Diabetes Prevention Trial-Type 1 Diabetes (DPT1), sponsored by the National Institutes of Health in the United States. Currently, -60,000 first-degree relatives are being screened for ICA to identify about 400 high-risk subjects with high-titer ICA and impaired 13 cell function, who will be randomized to parenteral insulin or control groups.
Double-blind trials of oral bovine myelin in multiple sclerosis (26) and type II chicken collagen in rheumatoid arthritis (27) have recently been reported. Although promising, these trials did not unequivocally demonstrate the efficacy of antigen-specific oral tolerance in humans. This has, however, recently been established by Husby et al. (28) in a seminal study with the experimental antigen, keyhole limpet hemocyanin (KLH). KLH ingestion significantly reduced T cell proliferation and the skin DTH response, and increased the antibody response, to subsequent KLH immunization. This deviation of immunity from T cell to B cell responses was previously reported after feeding low doses of soluble protein antigens to mice (13) . A trial of oral insulin in high-risk ICA-positive relatives is planned in the National Institutes of Health-sponsored intervention program.
Nasopharyngeal or respiratory delivery of soluble protein also induces tolerance at the T cell level. In fact, acetylated N-terminal peptides of myelin basic protein that induce EAE when given subcutaneously with adjuvant protect against disease induction if first given intranasally, but not if first given orally (29) . Intranasal or aerosol inhalation might therefore be the preferred route for the induction of mucosal tolerance, at least for certain peptides. Clinical trials of intranasal or aerosol antigens have not been reported in humans, but Waldo et al. (30) recently showed that KLH given intranasally to adult volunteers resulted in T cell tolerance with deviation from T cell to B cell immunity.
Oral, aerosol or intranasal insulin should be acceptable and practical tolerogenic modes of delivering insulin. Certainly, they would seem preferable to parenteral insulin in young people at risk for IDDM, in whom an objective of intervention treatment is to abolish the need for daily injections! The impetus to embark on intervention trials is strong but the scientific rationale is still relatively weak and many questions pertinent to guiding intervention in humans remain unanswered. The study of Zhang et al. (4) (33) and evaluated subsequently in clinical trials as a possible hypoglycaemic (34) . Compared with oral insulin, intranasal insulin might have the advantages of a lower dose requirement, more direct delivery to the mucosa, less degradation and variability of adsorption and therefore less interdose variance of delivery. What are the immunogenic and tolerogenic T cell epitopes within (pro)insulin? Are there reliable and reproducible surrogate markers (e.g., insulin-reactive T cells) with which to monitor whether immunotherapy is likely to have the expected long-term effect of reducing the incidence of clinical disease?
These are important practical questions, the answers to which would take some of the guesswork out of the design of human trials. Proposed large-scale trials of insulin-based immunotherapy in at-risk relatives could do well to proceed cautiously while addressing these questions, despite pressure for action from various interested parties. There is not only an ethical obligation to provide a reasonably sound scientific rationale, but the logistics and costs of intervention trials are daunting.
